Senior Director, Cell Biology & Process Development,
Catalent Pharma Solutions
Laura Daley, PhD is a senior director at Catalent Pharma Solutions where she supports cell line development, R&D, and cell & molecular biology activities. Laura received her doctoral degree in pharmacology and physiology from the Saint Louis University School of Medicine. She has over 17 years of industry experience in stem cell biology and gene editing and continues to leverage her expertise in developing innovative platforms for protein manufacturing at Catalent.
About this event:
Date:February 10, 2026
Time:11 am EST | 8 am PST | 5 pm CET
Duration:15 minutes
Biopharma innovators face increasing pressure to advance monoclonal antibody programs to IND quickly without compromising product quality or downstream scalability. Yet, traditional timelines often extend beyond 12 months, creating delays that impact patient access and increase development costs.
This webcast will explore how Catalent’s Rapid Antibody platform delivers GMP drug substance in as little as eight months, enabling IND readiness and first-in-human studies faster. Catalent's expert, Laura Daley, PhD, will explain the integrated approach that combines robust cell line development and process optimization. This approach is supported by US-based GMP manufacturing, enabling aggressive timelines without sacrificing control or scalability.
Key Takeaways:
Introducing Catalent’s Rapid Antibody platform and how it accelerates development for traditional monoclonal antibodies.
Understanding the new eight-month timeline from gene construct to GMP drug substance for IND readiness.
Learning what makes this approach different—integrated development and manufacturing designed for speed, control, and scalability.
